Back to Search
Start Over
1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
- Source :
-
Annals of Oncology . 2023 Supplement 2, Vol. 34, pS848-S849. 2p. - Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 34
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 173099258
- Full Text :
- https://doi.org/10.1016/j.annonc.2023.09.2538